Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**dexamethasone + timolol** is a combination of two well-established drugs used in ophthalmology: dexamethasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects, and timolol, a nonselective beta-adrenergic antagonist. While each agent has its own indications and mechanisms—dexamethasone is used for reducing inflammation and timolol for lowering intraocular pressure (IOP) in ocular hypertension and glaucoma—their combination is not a standard, commercially available fixed-dose product. However, there is clinical evidence that pretreatment with dexamethasone can enhance the acute ocular hypotensive effect of timolol, suggesting a potential synergistic effect in lowering IOP, particularly in the context of ocular hypertension and glaucoma[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + timolol.